Codexis (CDXS) Competitors $2.52 +0.02 (+0.80%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$2.68 +0.16 (+6.35%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. ZBIO, GERN, MYGN, VSTM, LXRX, RIGL, EBS, XOMA, VNDA, and IRWDShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Zenas BioPharma Geron Myriad Genetics Verastem Lexicon Pharmaceuticals Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Ironwood Pharmaceuticals Codexis (NASDAQ:CDXS) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Does the media favor CDXS or ZBIO? In the previous week, Zenas BioPharma had 51 more articles in the media than Codexis. MarketBeat recorded 54 mentions for Zenas BioPharma and 3 mentions for Codexis. Codexis' average media sentiment score of 0.77 beat Zenas BioPharma's score of 0.67 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 13 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CDXS or ZBIO more profitable? Zenas BioPharma has a net margin of 0.00% compared to Codexis' net margin of -113.67%. Zenas BioPharma's return on equity of -59.21% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Codexis-113.67% -105.83% -46.06% Zenas BioPharma N/A -59.21%-50.56% Which has better earnings and valuation, CDXS or ZBIO? Codexis has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCodexis$59.35M3.83-$65.28M-$0.83-3.04Zenas BioPharma$5M217.71-$156.99M-$3.55-7.28 Do analysts prefer CDXS or ZBIO? Codexis presently has a consensus target price of $11.00, indicating a potential upside of 336.51%. Zenas BioPharma has a consensus target price of $38.33, indicating a potential upside of 48.29%. Given Codexis' higher possible upside, equities research analysts clearly believe Codexis is more favorable than Zenas BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Codexis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Zenas BioPharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders believe in CDXS or ZBIO? 78.5% of Codexis shares are held by institutional investors. 1.9% of Codexis shares are held by company insiders. Comparatively, 16.5% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCodexis beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.67M$3.35B$6.03B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-3.0421.9084.6227.24Price / Sales3.83263.76497.57196.92Price / CashN/A46.9537.5761.53Price / Book3.0710.4312.356.74Net Income-$65.28M-$52.58M$3.32B$276.59M7 Day Performance-4.55%-1.55%-1.32%-0.47%1 Month Performance3.28%12.96%8.15%7.47%1 Year Performance-25.66%15.43%73.83%34.58% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis2.9297 of 5 stars$2.52+0.8%$11.00+336.5%-21.7%$225.67M$59.35M-3.04250ZBIOZenas BioPharma2.259 of 5 stars$23.03+5.8%$36.67+59.2%N/A$916.31M$15M-6.49N/ANews CoverageInsider TradeAnalyst RevisionGap DownGERNGeron2.4909 of 5 stars$1.28-5.2%$3.79+195.8%-70.0%$861.32M$76.99M-9.8570News CoverageMYGNMyriad Genetics3.5688 of 5 stars$7.99-0.9%$12.45+55.9%-68.9%$749.94M$837.60M-1.872,700News CoverageAnalyst ForecastVSTMVerastem2.7465 of 5 stars$8.61-1.0%$13.29+54.3%+200.0%$535.44M$10K-2.6350News CoverageLXRXLexicon Pharmaceuticals2.7655 of 5 stars$1.55+9.9%$3.23+108.1%-18.4%$512.39M$31.08M-4.70140News CoverageRIGLRigel Pharmaceuticals3.7876 of 5 stars$28.90+1.3%$38.20+32.2%+81.1%$511.93M$179.28M5.34160EBSEmergent Biosolutions4.2505 of 5 stars$9.16+0.1%$13.50+47.4%+1.4%$488.16M$1.04B3.742,420Gap DownXOMAXOMA Royalty4.1229 of 5 stars$36.61-7.8%$69.50+89.8%+31.1%$480.12M$28.49M-23.6210Gap DownVNDAVanda Pharmaceuticals4.122 of 5 stars$5.40-0.6%$16.50+205.6%+8.7%$320.85M$198.77M-4.78290IRWDIronwood Pharmaceuticals4.469 of 5 stars$1.48-4.5%$4.94+233.8%-65.5%$251.77M$308.52M-29.59220News CoveragePositive News Related Companies and Tools Related Companies ZBIO Alternatives GERN Alternatives MYGN Alternatives VSTM Alternatives LXRX Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives VNDA Alternatives IRWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
